Table 10.

Highlights the chemotherapeutic drugs associated with a high risk of occult hepatitis B virus infection reactivation

Drug	Mechanism of action	Ref.
Rituximab	Anti-CD20 monoclonal antibody	[111-113]
Rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone	Rituximab: Anti-CD20 monoclonal antibody	[117]
	Cyclophosphamide: Alkylating agent, inhibits protein synthesis by DNA and RNA crosslinking
	Hydroxydaunorubicin: Inhibits DNA replication and cell production
	Oncovin: Vinca alkaloid, microtubule-disrupting agent. Prednisolone: Suppression of migration of polymorphonuclear lymphocytes and reversal of increased capillary permeability
Ofatumumab; Alemtuzumab; Baricitinib	Anti-CD20 monoclonal antibody; Anti-CD52 monoclonal antibody; Janus kinase inhibitor	[111,118]